We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Growing European Market for Nucleic Acid Isolation

By Biotechdaily staff writers
Posted on 25 Jul 2006
The significance of nucleic acid and its many applications in a large number of research fields has increased the demand for pure isolations in Europe. More...
Because nucleic acid is the fundamental substance preceding all other procedures in drug research, its integrity can enhance or damage research quality.

Frost & Sullivan (Palo Alto, CA, USA), an international growth consultancy company, finds that genomics markets/nucleic acid isolation markets in Europe earned revenues of U.S.$670.0 million in 2005 and estimates this will reach $1,490.2 million in 2012.

Incorporation of automation and robotics in the isolation of nucleic acid also plays a crucial role in meeting demand for purity. Further technologic value addition will only spur the instrumentation revenues in the market.

In this environment, automation has become instrumental in optimizing sample preparation stages--particularly for low- and medium-throughput operations. Suppliers of automation equipment to research institutions and pharmaceutical companies continually try to meet customers' demand for an open platform technology base with reagents and consumables.

"Automation vendors are working toward knowing their customers' needs, and customizing their solutions to ensure maximum satisfaction,” remarked Frost & Sullivan research analyst Charanya Ramachandran.

The market is very dynamic as brand restrictions and customer loyalty present problems for new participants. There is tremendous competition within the DNA as well as the RNA segments, which challenges an entrant to the market. Most end-users in this market give importance to reliability in their instrumentation suppliers, and therefore, brand loyalty is very high. Vendors with enough visibility and a proven market record, particularly in the case of reagents and purification kits that produce nucleic acid molecules with maximum purity, are able to make profits.

The best strategy for a niche participant would be to form a strategic alliance with a larger brand to gain better visibility. Furthermore, suppliers could offer a complete optimal cost solutions base using innovative technology, since the demand for stand-alone purification instrumentation is not very high.

"Some factors which can enhance a company's position within the market include forming strategic alliances or exclusive licensing agreements with a major innovative technology vendor,” noted Ms. Ramachandran.

Reliable service, accuracy, and quality, as well as attractive customer schemes could gain customer loyalty over time. Established suppliers could maintain and increase their base by building on customer loyalties through loyalty programs and a combination of selling and pricing strategies.



Related Links:
Frost & Sullivan

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Multi-Chamber Washer-Disinfector
WD 390
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.